Pharmacogenetics of TNFi Response in Rheumatoid Arthritis Utilising the Two-Component Disease Activity Score

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • S. S. A. Gilani
  • A. W. Morgan
  • A. G. Wilson
  • J. D. Isaacs
  • James Bluett

Abstract

Aim: TNF inhibitor (TNFi) drugs are a treatment option for rheumatoid arthritis (RA), but response is not universal. Response is typically measured using the composite 4-component (4C) disease activity score 28 (DAS28) which contains more subjective measures. This study used a validated 2-component (2C) DAS28 score to determine whether SNPs associated with response were replicated in a UK population. Materials & Methods: A literature review identified TNFi response SNPs. Linear regression was conducted to replicate associations with 4C or 2C-DAS28 response. Results: 18 independent SNPs were analysed in 1828 patients. One and four associations with 4C and 2C-DAS28 response respectively were identified (P<0.05). Conclusion: Further genetic associations were replicated using the 2C-DAS28 which may reflect the objective nature of 2C-DAS28.

Bibliographical metadata

Original languageEnglish
JournalPharmacogenomics
Publication statusAccepted/In press - 17 Aug 2020